Saliva samples for detection of SARS-CoV-2 in mildly symptomatic and asymptomatic patients.
Adolescent
Adult
Aged
Asymptomatic Diseases
COVID-19
/ diagnosis
COVID-19 Testing
/ methods
Child
Child, Preschool
Cohort Studies
Female
Health Personnel
Humans
Male
Middle Aged
Nasopharynx
/ virology
RNA, Viral
/ isolation & purification
Real-Time Polymerase Chain Reaction
SARS-CoV-2
/ genetics
Saliva
/ virology
Specimen Handling
Young Adult
Covid-19
RT-PCR
SARS-CoV-2
diagnosis
saliva
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
24
12
2020
accepted:
16
01
2021
pubmed:
28
1
2021
medline:
4
5
2021
entrez:
27
1
2021
Statut:
ppublish
Résumé
The ongoing coronavirus disease 2019 (Covid-19) pandemic has been rapidly spreading throughout the world with confirmed case numbers already exceeding 75 million. Although nasopharyngeal swabs are the most commonly utilized samples for based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA detection, collecting these specimens requires healthcare workers and necessitates the use of personal protective equipment as it presents a nosocomial transmission risk. We aimed to assess the diagnostic value of saliva samples in mildly symptomatic and asymptomatic patients with confirmed Covid-19. We performed a cohort study to validate the use of saliva for SARS-CoV-2 detection in mildly symptomatic and asymptomatic patients with a confirmed diagnosis of Covid-19. Saliva samples of the patients were analyzed by reverse-transcriptase polymerase chain reaction (RT-PCR). In May 2020, 28 asymptomatic and 25 mildly symptomatic patients were enrolled in the study. The median age was 37 years (range 4-70). None of the patients had a fever on presentation. Among 53 patients with SARS-CoV-2 detected in the nasopharyngeal sample, the real-time RT-PCR was positive in the saliva specimens in 48 (90.56%) patients. The mean cycle threshold (CT) values for nasopharyngeal and saliva specimens (27.80 ± 3.44 and 30.64 ± 2.83, respectively) were significantly correlated between the two sample types (p = .016). The mean CT values of nasopharyngeal and saliva samples in mildly symptomatic and asymptomatic patients (27.18 ± 3.53 and 30.24 ± 3.29 vs. 28.36 ± 3.31 and 30.98 ± 2.39, respectively) were not significantly different (p = .236 and p = .733, respectively). Saliva specimens can be considered as a reliable and less resource-intensive alternative to nasopharyngeal specimens for screening asymptomatic SARS-CoV-2 infections.
Sections du résumé
BACKGROUND
The ongoing coronavirus disease 2019 (Covid-19) pandemic has been rapidly spreading throughout the world with confirmed case numbers already exceeding 75 million. Although nasopharyngeal swabs are the most commonly utilized samples for based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA detection, collecting these specimens requires healthcare workers and necessitates the use of personal protective equipment as it presents a nosocomial transmission risk. We aimed to assess the diagnostic value of saliva samples in mildly symptomatic and asymptomatic patients with confirmed Covid-19.
METHODS
We performed a cohort study to validate the use of saliva for SARS-CoV-2 detection in mildly symptomatic and asymptomatic patients with a confirmed diagnosis of Covid-19. Saliva samples of the patients were analyzed by reverse-transcriptase polymerase chain reaction (RT-PCR).
RESULTS
In May 2020, 28 asymptomatic and 25 mildly symptomatic patients were enrolled in the study. The median age was 37 years (range 4-70). None of the patients had a fever on presentation. Among 53 patients with SARS-CoV-2 detected in the nasopharyngeal sample, the real-time RT-PCR was positive in the saliva specimens in 48 (90.56%) patients. The mean cycle threshold (CT) values for nasopharyngeal and saliva specimens (27.80 ± 3.44 and 30.64 ± 2.83, respectively) were significantly correlated between the two sample types (p = .016). The mean CT values of nasopharyngeal and saliva samples in mildly symptomatic and asymptomatic patients (27.18 ± 3.53 and 30.24 ± 3.29 vs. 28.36 ± 3.31 and 30.98 ± 2.39, respectively) were not significantly different (p = .236 and p = .733, respectively).
CONCLUSIONS
Saliva specimens can be considered as a reliable and less resource-intensive alternative to nasopharyngeal specimens for screening asymptomatic SARS-CoV-2 infections.
Identifiants
pubmed: 33501645
doi: 10.1002/jmv.26821
pmc: PMC8013767
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2932-2937Subventions
Organisme : Bioeksen (Bioeksen R&D, Istanbul, Turkey)
Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Lancet Infect Dis. 2020 Jun;20(6):656-657
pubmed: 32199493
Science. 2020 May 1;368(6490):489-493
pubmed: 32179701
J Med Virol. 2021 May;93(5):2932-2937
pubmed: 33501645
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
Clin Infect Dis. 2020 Jul 28;71(15):841-843
pubmed: 32047895
China CDC Wkly. 2020 Jan 24;2(4):61-62
pubmed: 34594763
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
J Clin Microbiol. 2016 Dec 28;55(1):226-233
pubmed: 27807150
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
N Engl J Med. 2020 Apr 30;382(18):e41
pubmed: 32212516
Front Med (Lausanne). 2020 Aug 04;7:465
pubmed: 32903849
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
Emerg Microbes Infect. 2017 Jun 7;6(6):e49
pubmed: 28588283
J Infect. 2020 Jul;81(1):e45-e50
pubmed: 32298676
Ann Intern Med. 2020 Jun 2;172(11):726-734
pubmed: 32282894